Firefly Neuroscience (NASDAQ:AIFF) Trading 0.6% Higher – Here’s Why

Shares of Firefly Neuroscience, Inc. (NASDAQ:AIFF) traded up 0.6% on Tuesday . The stock traded as high as $1.6820 and last traded at $1.61. 185,285 shares traded hands during mid-day trading, a decline of 50% from the average session volume of 373,226 shares. The stock had previously closed at $1.60.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wall Street Zen upgraded shares of Firefly Neuroscience from a “sell” rating to a “hold” rating in a research report on Saturday, May 16th. Weiss Ratings upgraded shares of Firefly Neuroscience from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, May 19th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company currently has an average rating of “Sell”.

Firefly Neuroscience Trading Up 0.6%

The business’s fifty day simple moving average is $1.83 and its 200 day simple moving average is $1.48. The stock has a market cap of $25.07 million, a price-to-earnings ratio of -2.56 and a beta of 0.52.

Firefly Neuroscience (NASDAQ:AIFF) last released its earnings results on Tuesday, May 12th. The company reported ($0.13) EPS for the quarter. Firefly Neuroscience had a negative return on equity of 94.68% and a negative net margin of 565.40%.The business had revenue of $0.49 million for the quarter.

Institutional Trading of Firefly Neuroscience

Institutional investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Firefly Neuroscience during the 4th quarter worth $53,000. Savvy Advisors Inc. acquired a new stake in Firefly Neuroscience during the 3rd quarter worth $63,000. Geode Capital Management LLC grew its holdings in Firefly Neuroscience by 92.9% during the 2nd quarter. Geode Capital Management LLC now owns 120,604 shares of the company’s stock worth $341,000 after acquiring an additional 58,067 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Firefly Neuroscience by 393.3% during the 3rd quarter. Vanguard Group Inc. now owns 503,071 shares of the company’s stock worth $1,464,000 after acquiring an additional 401,085 shares during the period. Institutional investors and hedge funds own 4.96% of the company’s stock.

Firefly Neuroscience Company Profile

Firefly Neuroscience is a clinical‐stage neurotechnology company focused on developing digital biomarkers and cognitive assessment tools for the early detection and monitoring of neurological disorders. The company’s platform combines mobile applications, sensor technology and advanced analytics to capture objective brain function data outside of traditional clinical settings. By providing real‐world cognitive and physiological measurements, Firefly aims to improve diagnosis, track disease progression and support therapeutic development.

The company’s flagship offering is a smartphone‐based cognitive assessment app that guides users through a series of interactive tasks designed to measure attention, memory, processing speed and executive function.